In this paper, we discuss the philosophical and psychopathological background of Domain 3, Other persons, of the Examination of Anomalous World Experiences (EAWE). The EAWE interview aims to describe the manifold phenomena of the schizophrenic lifeworld in all of their concrete and distinctive features, thus complementing a more abstract, symptom-focused approach. Domain 3, Other persons, focuses specifically on subjectively experienced interpersonal disturbances that may be especially common in schizophrenia. The aim of this domain, as with the rest of the EAWE, is to provide clinicians and researchers with a systematic orientation toward, or knowledge of, patients' experiences, so that the experiential universe of schizophrenia can be clarified in terms of the particular feel, meaning, and value it has for the patient. To help provide a context for EAWE Domain 3, Other persons, we propose a definition of “intersubjectivity” (IS) and “dissociality.” The former is the ability to understand other persons, that is, the basis of our capacity to experience people and social situations as meaningful. IS relies both on perceptive- intuitive as well as cognitive-computational resources. Dissociality addresses the core psychopathological nucleus characterizing the quality of abnormal IS in persons with schizophrenia and covers several dimensions, including disturbances of both perceptive-intuitive and cognitive-computational capacities. The most typical perceptive-intuitive abnormality is hypoattunement, that is, the lack of interpersonal resonance and difficulties in grasping or immediately understanding others' mental states. The most characteristic cognitive-computational anomaly is social hyperreflexivity, especially an algorithmic conception of sociality (an observational/ethological attitude aimed to develop an explicit, often rule-based personal method for participating in social transactions). Other anomalous interpersonal experiences, such as emotional and behavioral responses to others, are also discussed in relation to this core of dissociality.

Keywords:
Autism, Dissociality, Intersubjectivity, Subjective experience, Social dysfunction, Social hyperreflexivity, Schizophrenia
1.
Stanghellini G, Rossi R: Pheno-phenotypes: a holistic approach to the psychopathology of schizophrenia. Curr Opin Psychiatry 2014;27:236-241.
2.
Stanghellini G, Ballerini M: Qualitative analysis. Its use in psychopathological research. Acta Psychiatr Scand 2008;117:161-163.
3.
Ballerini M: Phenomenological psychopathology and qualitative research; in Broome M, Fernandez A, Fusar-Poli P, Raballo A, Rosfort R, Stanghellin G (eds) Oxford Handbook of Phenomenological Psychopathology. Oxford, Oxford University Press, in press.
4.
Stanghellini G, Broome MR: Psychopathology as the basic science of psychiatry. Br J Psychiatry 2014;205:169-170.
5.
Stanghellini G: Lost in Dialogue. Anthropology, Psychopathology, and Care. Oxford/New York, Oxford University Press, 2016.
6.
Stanghellini G, Ballerini M: What is it like to be a person with schizophrenia in the social world? A first-person perspective study on schizophrenic dissociality - part 1. State of the art. Psychopathology 2011;44:172-182.
7.
Stanghellini G, Ballerini M: What is it like to be a person with schizophrenia in the social world? A first-person perspective study on schizophrenic dissociality - part 2. Methodological issues and empirical findings. Psychopathology 2011;44:183-192.
8.
Sass L, Pienkos E, Skodlar B, Stanghellini G, Fuchs T, Parnas J, Jones N: EAWE: Examination of Anomalous World Experience. Psychopathology 2017;50:10-54.
9.
Gallagher S, Zahavi D: The Phenomenological Mind, ed 2. London/New York, Routledge, 2012.
10.
Gopnik A, Wellman H: Why the child's theory of mind really is a theory. Mind Lang 1992;7:145-171.
11.
Gordon R: Folk psychology as simulation. Mind Lang 1986;1:158-171.
12.
Gallagher S: Intersubjectivity and psychopathology; in Fulford KWM, Davies M, Gipps RGT, Graham G, Sadler JZ, Stanghellini G, Thornton T (eds): The Oxford Handbook of Philosophy and Psychiatry. Oxford, Oxford University Press, 2013, pp 258-274.
13.
Hutto DD: Interpersonal relating; in Fulford KWM, Davies M, Gipps RGT, Graham G, Sadler JZ, Stanghellini G, Thornton T (eds): The Oxford Handbook of Philosophy and Psychiatry. Oxford, Oxford University Press, 2013, pp 249-257.
14.
Scheler M: Wesen und Formen der Sympathie. Bern/Munich, Francke, 1973.
15.
Johnson SC: The recognition of mentalistic agents in infancy. Trends Cogn Sci 2000;4:22-28.
16.
Ammaniti M, Gallese V: The Birth of Intersubjectivity. New York/London, Norton, 2014.
17.
Merleau-Ponty M: Phénoménologie de la perception. Paris, Gallimard, 1945.
18.
Hutto DH: The narrative practice hypothesis. Origins and application of folk psychology; in Hutto DH (ed): Narrative and Understanding Persons. Cambridge, Cambridge University Press, 2007, pp 43-88.
19.
Ballerini M: Autism in schizophrenia. A phenomenological study; in Stanghellini G, Aragona M (eds): An Experiential Approach to Psychopathology. Heidelberg/New York, Springer, 2016, pp 281-300.
20.
Froese T, Stanghellini G, Bertelli MO: Is it normal to be a principal mindreader? Revising theories of social cognition on the basis of schizophrenia and high functioning autism-spectrum disorders. Res Dev Disabil 2013;34:1376-1387.
21.
Bleuler E: Dementia praecox oder Gruppe der Schizophrenien. Leipzig, Deuticke, 1911.
22.
Kretschmer E: Körperbau und Charakter. Berlin, Springer, 1961.
23.
Parnas J, Bovet P, Zahavi D: Schizophrenic autism: clinical phenomenology and pathogenetic implication. World Psychiatry 2002;1:131-136.
24.
Minkowski E: La schizophrénie. Psychopathologie des schizoïdes et des schizophrènes. Paris, Payot, 1927.
25.
Blankenburg W: Der Verlust der natürlichen Selbstverständlichkeit. Stuttgart, Enke, 1971.
26.
Sass L, Pienkos E: Faces of intersubjectivity: a phenomenological study of interpersonal experience in melancholia, mania, and schizophrenia. J Phenom Psychol 2015;46:1-32.
27.
Stanghellini G: Psicopatologia del senso comune. Milano, Cortina, 2007.
28.
Sasson NJ, Pinkham AE, Carpenter KLH, Belger A: The benefit of directly comparing autism and schizophrenia for revealing mechanisms of social cognitive impairment. J Neurodev Disord 2011;3:87-100.
29.
Stanghellini G, Ballerini M: Autism: disembodied existence. Philos Psychiatry Psychol 2004;11:259-268.
30.
Straus E: Vom Sinn der Sinne. Berlin, Springer, 1935.
31.
Stanghellini G, Ballerini M: Dis-sociality: the phenomenological approach to social dysfunction in schizophrenia. World Psychiatry 2002,1:102‒106.
32.
Stanghellini G, Rosfort R: Emotions and Personhood. Oxford, Oxford University Press, 2013.
33.
Stanghellini G, Ballerini M, Lysaker PH: Autism Rating Scale. J Psychopathol 2014;20:273-285.
34.
Stanghellini G, Ballerini M: Criterion B (social dysfunction) in persons with schizophrenia: the puzzle. Curr Opin Psychiatry 2007;20:582-587.
35.
Stanghellini G, Ballerini M: Values in persons with schizophrenia. Schizophr Bull 2007;33:131-141.
36.
Pienkos E, Sass L: Existential orientation: on the phenomenology of values, attitudes, and worldviews in schizophrenia (ancillary article to EAWE domain 6). Psychopathology 2017; 50:98-104.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.